Neurology

EverythingALS Launches the Vision 2030 AI Hub: Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research

Retrieved on: 
Tuesday, March 12, 2024
Research, Neurology, Harvard Medical School, Synthetic media, Machine learning, Government, Regeneration, Prevalence, Massachusetts General Hospital, Science, Environment, MIT, Data science, SAN, Knowledge, Biomarker, History, Hope, Doctor of Philosophy, LLM, Vision 2030, Hub, Ecosystem, Drug development, Navar, Frontotemporal dementia, Artificial intelligence, Generative, Mass, Medicine, Medical device

The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.

Key Points: 
  • The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
  • The Vision 2030 AI Hub epitomizes this momentous convergence—where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery.
  • The Vision 2030 AI Hub motivates giving and fundraising, showcasing an innovative operating model that emphasizes urgency in tackling ALS and other disorders.
  • For more information about EverythingALS, Vision 2030, and the AI Hub visit http://www.v2030.org or email us at [email protected] .

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Retrieved on: 
Saturday, April 6, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, TEVA, De novo, Patient, Interview, NNH, Tardive dyskinesia, Congress, Medication, Risperidone, International, Risk, NNT, Caregiver, Safety, HCP, Emotion, Teva Pharmaceuticals, Health professional, Data wrangling, Death, Lais, Teva, FDA, Olanzapine, SIRS, Perception, Physician, Schizophrenia International Research Society, Persistence

The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.

Key Points: 
  • The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
  • “Schizophrenia is a complex mental health condition where the treatment needs and preferences of those living with it may evolve over time.
  • In the patient survey, approximately 20 patients and 19 caregivers completed a 60-minute interview regarding the use of LAIs in schizophrenia.
  • Below is the full set of data presented by Teva at SIRS 2024.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Common stock, Therapy, Epilepsy, Employment, Compensated emancipation, Medication

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • These stock option grants have an exercise price of $8.68 per share, which is equal to the closing price of the Common Stock on April 4, 2024 (date of grant for such stock options).
  • These stock options were granted as inducements material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

Drug Discovery and Early Development Outsourcing Services Industry Analysis - M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, ChromeOS, ROI, Growth, Neurology, PROTAC, Drug discovery, Partnership, COVID-19, HTS, NGS, RNA, Artificial intelligence, Overalls, Drug development, Machine learning, Fine chemical

The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.
  • Overall R&D expenditure totals about $276.81 billion, with a slow 2.5% growth between 2023 to 2024.
  • This activity is improving the partnership landscape across the global drug discovery and preclinical development industry.
  • Last, the larger CROs have developed separate lab testing divisions that allow them to focus on specific drug discovery and preclinical development testing services.

AltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease

Retrieved on: 
Friday, April 5, 2024
Research, Neurology, Publishing, Communications, Clinical Trials, Biotechnology, Managed Care, Health, Science, Plasma, Scientific Reports, Patient, University, Amyloid, Neuropathology, MCI, Pharmaceutical industry

The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.

Key Points: 
  • The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.
  • The SOBA-AD blood test targets toxic soluble oligomers, an early molecular trigger of amyloid diseases, with the ultimate goal of identifying patients with the disease years before symptoms manifest.
  • The SOBA-AD blood test identified AD patients from cognitively unimpaired (CU) subjects with 100% sensitivity, >95% specificity, and >98% area under the curve (95% CI 0.95-1.00).
  • These results for our simple SOBA-AD blood test support the goal of earlier, pre-symptomatic detection of patients with AD.

Global Microbiome Manufacturing Markets 2023-2024 & 2035: Industry Trends, Forecasts, Formulation, Primary Packaging Used, Scale of Operation, Company Size, Key Regions and Leading Developers - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Vitamins, Supplements, Neurology, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, General Health, Pharmaceutical, Health, Clostridioides difficile infection, Type, Organization, Database, AOBiome, Microbiota, Patient, CNS, CGMP, Research, Fungus, FDF, Bacteria, Virus, Laboratory, Overalls, Infection, DSM-IV codes, API, Safety, Phase, Therapy, USD, LBP

Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.

Key Points: 
  • Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.
  • Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies.
  • This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, UBE2M, Oak Ridge National Laboratory, Neurology, Prostate cancer, Serum, FLNA, Drug discovery, Patient, GBM, Hospital, Research, Cancer, University, Hope, Deep learning, AACR, Clinical trial, Drug development, University of Tennessee, Immune system, Stanford University, Multimedia, Netherlands Architecture Institute

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Key Points: 
  • BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.
  • The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240405006693/en/
    A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire)
    New data further validating the mitochondrial-centric effect of BPM31510 on the immune system.

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on: 
Thursday, April 4, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points: 
  • GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
  • Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
  • GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
  • As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

XCath CEO Eduardo Fonseca Spotlights AI in Endovascular Robotics at SLICE Next Frontiers Conference

Retrieved on: 
Thursday, April 4, 2024
Neurology, General Health, Health, Artificial Intelligence, Medical Devices, Robotics, Health Technology, Technology, AI, Conference, Exhibition, DRS

XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .

Key Points: 
  • XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires, presented at the annual SLICE Next Frontiers Conference hosted by Dr. Vincent Costalat and Master and Fellow .
  • “The SLICE Next Frontiers conference convenes thought leaders from across the neuro space and is a key opportunity to learn about current innovations and where we’re going next,” said Fonseca.
  • “In conversations that took place at the event about robotics, AI and telerobotics there was a lot of enthusiasm about how these technologies can enhance patient care.
  • These objectives are all top of mind at XCath, and we look forward to being part of the future of neurovascular interventions.”
    For more information about the SLICE Next Frontiers Conference, visit https://masterandfellow.com/slice/nf .